Latest News

 Filter by Provider

Solventum Corp (NYSE:SOLV) reported mixed Q2 2025 earnings, beating EPS estimates at $1.69 but slightly missing revenue forecasts. Shares rose 3% post-announcement.

Corvus Pharmaceuticals reported a narrower Q2 2025 loss of $0.10 per share, beating estimates, with shares rising 5.8% after-hours. Positive Phase 1 data for soquelitinib in atopic dermatitis boosted investor optimism.

APYX Medical Corp reported Q2 2025 results with revenue of $11.37M, missing estimates, but a narrower EPS loss of -$0.09. Stock shows muted reaction amid commercial expansion plans.

Rocket Lab reports second-quarter financial results after the market close on Thursday. Here's a rundown of the report.

Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026.

Texas Roadhouse Q2 2025 earnings missed revenue and EPS estimates, triggering a 2.7% stock drop. Dividend maintained at $0.68/share. Analysts provide Q3 and full-year forecasts.

Fertility benefits company Progyny (NASDAQ:PGNY) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.5% year on year to $332.9 million. Guidance for next quarter’s revenue was optimistic at $297.5 million at the midpoint, 2% above analysts’ estimates. Its non-GAAP profit of $0.48 per share was 12.1% above analysts’ consensus estimates.

PTC Therapeutics (PTCT) reported strong Q2 2025 earnings, beating revenue estimates at $179M and narrowing EPS loss. Growth driven by Sephience™ launch for PKU in U.S. & Europe. Stock up 5.4% in a month.

Intel shares tumbled more than 3% after President Donald Trump demanded CEO Lip‑Bu Tan resign over alleged conflicts related to China.

Monster Beverage Corp (MNST) reports mixed Q2 2025 results: EPS beats estimates at $0.52, while revenue slightly misses at $2.11B. Shares rise 3.8% post-earnings.

Arrowhead Pharmaceuticals reported mixed Q3 2025 results, beating revenue estimates but missing on EPS. Stock fell 5.3% as higher R&D costs widened losses. Key pipeline updates include plozasiran NDA submission and Phase 3 trial progress.

AudioEye Inc. reports mixed Q2 2025 results with record revenue but misses estimates, sparking a 10% stock drop. EPS beats forecasts, but revenue shortfall drives negative market reaction.

Akamai Technologies (AKAM) reported strong Q2 2025 earnings, beating revenue and EPS estimates with 7% YoY growth. Cloud Infrastructure surged 30%, driving a 3% after-hours stock rise.

NERDY INC (NYSE:NRDY) reported mixed Q2 2025 results, missing revenue estimates but beating EPS expectations. Stock fell 16% due to weak guidance and margin pressures. Consumer membership grew, but institutional revenue declined. AI investments aim for Q4 profitability.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.

The 25Q2 Y/Y blended earnings growth estimate is 73.7%. If the energy sector is excluded, the growth rate for the index is 95.7%.

CEFZ ETF launched, converting from RiverNorth Core Opportunity Fund. A trend of mutual fund-to-ETF conversions is gaining steam to improve investor experience and stay competitive in the market.

MicroVision (MVIS) Q2 2025 earnings missed revenue estimates but slightly beat EPS expectations. Revenue fell short at $0.2M, while net loss narrowed to $0.06/share. Stock dipped 3.58% post-report. Key updates include NVIDIA integration and defense sector progress.

CytoSorbents (CTSO) reported Q2 2025 results with revenue of $9.62M, beating estimates, and a narrower EPS loss of -$0.05. Shares rose 4.32% post-earnings amid steady demand for CytoSorb.

Doximity (DOCS) beats Q1 2026 earnings with $145.9M revenue (+15% YoY), EPS at $0.36 vs. $0.31 estimate. Stock jumps 8.4% on strong guidance & AI growth.

Take-Two Interactive Software reported strong Q1 results with net bookings of $1.42B, driven by popular games like GTA V and NBA 2K25. Company raises full-year outlook.

EOG Resources reports mixed Q2 2025 results, beating EPS estimates but slightly missing revenue. Stock dips 1% amid cautious market sentiment.

BioLife Solutions reports Q2 2025 revenue beat but faces profitability challenges, with mixed market reaction. Cell processing growth up 28% YoY.

Luxury hotels and casino operator Wynn Resorts (NASDAQ:WYNN) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $1.74 billion. Its non-GAAP profit of $1.09 per share was 9% below analysts’ consensus estimates.

Here's a look at The Trade Desk's Q2 report.

Online travel agency Expedia (NASDAQ:EXPE) announced better-than-expected revenue in Q2 CY2025, with sales up 6.4% year on year to $3.79 billion. Its non-GAAP profit of $4.24 per share was 2.7% above analysts’ consensus estimates.

Manulife John Hancock Investments has expanded its ETF presence with a new ETF, managed by David Cohen and Joshua White.

Software development tools maker JFrog (NASDAQ:FROG) announced better-than-expected revenue in Q2 CY2025, with sales up 23.5% year on year to $127.2 million. Guidance for next quarter’s revenue was better than expected at $128 million at the midpoint, 1.6% above analysts’ estimates. Its non-GAAP profit of $0.18 per share was 10.1% above analysts’ consensus estimates.

Take-Two Interactive Software crushed Wall Street's targets for its fiscal Q1 and raised its full-year guidance. Take-Two stock rose.

Trump will nominate Stephen Miran to the Federal Reserve Board, giving him a vote on interest rates until January 2026.